

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

Yes

One stakeholder noted geographic deliverability of the therapy to be considered for equality of access.

One stakeholder advised that young people are less likely to be included in clinical trials.
--

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

Physical access to treatments may present implementation issues in certain circumstances. Where appropriate, issues related to the implementation of a technology may be considered by the committee during the appraisal, but this is not likely to be an equality issue that can be addressed by a NICE technology appraisal recommendation.
--

Age is a protected characteristic. However, it is beyond the committee's remit to consider equality in clinical trial recruitment.
--

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
--

No

Approved by Associate Director (name): ...Janet Robertson.....

Date: 08 January 2025